{"id":758384,"title":"Archived 19: Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-02-21","captureTimestamp":"2026-02-21T22:00:28.161000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html","snippet":"Archived 19: Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series Notice to reader This is an archived version. Please refer to current COVID-19…","rawSnapshotUrl":"/api/snapshots/raw/758384","browseUrl":"https://replay.healtharchive.ca/job-7/20260221220028/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html#ha_snapshot=758384","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}